Zobrazeno 1 - 10
of 61
pro vyhledávání: '"Elaine Cadogan"'
Autor:
Elizabeth L. Hardaker, Emilio Sanseviero, Ankur Karmokar, Devon Taylor, Marta Milo, Chrysis Michaloglou, Adina Hughes, Mimi Mai, Matthew King, Anisha Solanki, Lukasz Magiera, Ricardo Miragaia, Gozde Kar, Nathan Standifer, Michael Surace, Shaan Gill, Alison Peter, Sara Talbot, Sehmus Tohumeken, Henderson Fryer, Ali Mostafa, Kathy Mulgrew, Carolyn Lam, Scott Hoffmann, Daniel Sutton, Larissa Carnevalli, Fernando J. Calero-Nieto, Gemma N. Jones, Andrew J. Pierce, Zena Wilson, David Campbell, Lynet Nyoni, Carla P. Martins, Tamara Baker, Gilberto Serrano de Almeida, Zainab Ramlaoui, Abdel Bidar, Benjamin Phillips, Joseph Boland, Sonia Iyer, J. Carl Barrett, Arsene-Bienvenu Loembé, Serge Y. Fuchs, Umamaheswar Duvvuri, Pei-Jen Lou, Melonie A. Nance, Carlos Alberto Gomez Roca, Elaine Cadogan, Susan E. Critichlow, Steven Fawell, Mark Cobbold, Emma Dean, Viia Valge-Archer, Alan Lau, Dmitry I. Gabrilovich, Simon T. Barry
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-20 (2024)
Abstract The Ataxia telangiectasia and Rad3-related (ATR) inhibitor ceralasertib in combination with the PD-L1 antibody durvalumab demonstrated encouraging clinical benefit in melanoma and lung cancer patients who progressed on immunotherapy. Here we
Externí odkaz:
https://doaj.org/article/189773f2417346dcbdf8b6281d57effa
Autor:
David Hodson, Hitesh Mistry, Sofia Guzzetti, Michael Davies, Anna Staniszewska, Paul Farrington, Elaine Cadogan, James Yates, Leon Aarons, Kayode Ogungbenro
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 11, Pp 1640-1652 (2023)
Abstract Dosage optimization to maximize efficacy and minimize toxicity is a potential issue when administering radiotherapy (RT) in combination with immune checkpoint blockade (ICB) or inhibitors of the DNA Damage Response Pathway (DDRi) in the clin
Externí odkaz:
https://doaj.org/article/6a94e1fb15584edda03e4b6cd2be34da
Autor:
Tudor Petreus, Elaine Cadogan, Gareth Hughes, Aaron Smith, Venkatesh Pilla Reddy, Alan Lau, Mark James O’Connor, Susan Critchlow, Marianne Ashford, Lenka Oplustil O’Connor
Publikováno v:
Communications Biology, Vol 4, Iss 1, Pp 1-11 (2021)
Petreus et al. describe a platform combining 3D tumour-on-chip technology and pump driven microfluidics to study drug effects at physiological exposures preclinically. They test colorectal cancer spheroids with combinations of two drugs and show that
Externí odkaz:
https://doaj.org/article/fe393dff3e4d4995a5151b725bf099ec
Autor:
Dharaminder Singh, Sudhir P Deosarkar, Elaine Cadogan, Vikki Flemington, Alysha Bray, Jingwen Zhang, Ronald S Reiserer, David K Schaffer, Gregory B Gerken, Clayton M Britt, Erik M Werner, Francis D Gibbons, Tomasz Kostrzewski, Christopher E Chambers, Emma J Davies, Antonio Ramos Montoya, Jacqueline H L Fok, David Hughes, Kristin Fabre, Matthew P Wagoner, John P Wikswo, Clay W Scott
Publikováno v:
PLoS Biology, Vol 20, Iss 5, p e3001624 (2022)
Test compounds used on in vitro model systems are conventionally delivered to cell culture wells as fixed concentration bolus doses; however, this poorly replicates the pharmacokinetic (PK) concentration changes seen in vivo and reduces the predictiv
Externí odkaz:
https://doaj.org/article/55008e3ff350462b806cde78444e0ef3
Autor:
Mark J. O'Connor, Judith Balmaña, Cristina Cruz, Christopher J. Lord, Elaine Cadogan, Josep V. Forment, J. Carl Barrett, Gordon B. Mills, Carlos Caldas, Brian Dougherty, Susan Critchlow, Alan Lau, Cristina Saura, Javier Cortés, Joaquin Arribas, Judit Grueso, Olga Rodríguez, Marta Guzman, Albert Gris-Oliver, Alejandra Bruna, Ambar Ahmed, Paul W.G. Wijnhoven, Adina Hughes, Zena Wilson, Jenni Nikkilä, Krishna C. Bulusu, Stephen J. Pettitt, Aditi Gulati, Rachel Brough, Alba Llop-Guevara, Filippos Michopoulos, Joshua Armenia, Zhongwu Lai, Gemma N. Jones, Andrea Herencia-Ropero, Marta Palafox, Urszula M. Polanska, Marta Castroviejo-Bermejo, Anderson T. Wang, Violeta Serra
Supplementary Data from Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ddb28e2b040877b2021a52cb106bd7a
https://doi.org/10.1158/1078-0432.22489322
https://doi.org/10.1158/1078-0432.22489322
Autor:
Mark J. O'Connor, Judith Balmaña, Cristina Cruz, Christopher J. Lord, Elaine Cadogan, Josep V. Forment, J. Carl Barrett, Gordon B. Mills, Carlos Caldas, Brian Dougherty, Susan Critchlow, Alan Lau, Cristina Saura, Javier Cortés, Joaquin Arribas, Judit Grueso, Olga Rodríguez, Marta Guzman, Albert Gris-Oliver, Alejandra Bruna, Ambar Ahmed, Paul W.G. Wijnhoven, Adina Hughes, Zena Wilson, Jenni Nikkilä, Krishna C. Bulusu, Stephen J. Pettitt, Aditi Gulati, Rachel Brough, Alba Llop-Guevara, Filippos Michopoulos, Joshua Armenia, Zhongwu Lai, Gemma N. Jones, Andrea Herencia-Ropero, Marta Palafox, Urszula M. Polanska, Marta Castroviejo-Bermejo, Anderson T. Wang, Violeta Serra
Supplementary Figure from Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4129939bd7a944921efb38cdb3344eaf
https://doi.org/10.1158/1078-0432.22489313.v1
https://doi.org/10.1158/1078-0432.22489313.v1
Autor:
Mark J. O'Connor, Judith Balmaña, Cristina Cruz, Christopher J. Lord, Elaine Cadogan, Josep V. Forment, J. Carl Barrett, Gordon B. Mills, Carlos Caldas, Brian Dougherty, Susan Critchlow, Alan Lau, Cristina Saura, Javier Cortés, Joaquin Arribas, Judit Grueso, Olga Rodríguez, Marta Guzman, Albert Gris-Oliver, Alejandra Bruna, Ambar Ahmed, Paul W.G. Wijnhoven, Adina Hughes, Zena Wilson, Jenni Nikkilä, Krishna C. Bulusu, Stephen J. Pettitt, Aditi Gulati, Rachel Brough, Alba Llop-Guevara, Filippos Michopoulos, Joshua Armenia, Zhongwu Lai, Gemma N. Jones, Andrea Herencia-Ropero, Marta Palafox, Urszula M. Polanska, Marta Castroviejo-Bermejo, Anderson T. Wang, Violeta Serra
Purpose:PARP inhibitors (PARPi) induce synthetic lethality in homologous recombination repair (HRR)-deficient tumors and are used to treat breast, ovarian, pancreatic, and prostate cancers. Multiple PARPi resistance mechanisms exist, most resulting i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::292ea7f6a2f41a4ddcc686cb101c0beb
https://doi.org/10.1158/1078-0432.c.6532931.v1
https://doi.org/10.1158/1078-0432.c.6532931.v1
Autor:
Caroline Dive, Mark J. O'Connor, Fiona Blackhall, Crispin Miller, Kathryn L. Simpson, Garima Khandelwal, Elaine Cadogan, Zhongwu Lai, Adina Hughes, Lynsey Priest, Cassandra L. Hodgkinson, Stewart Brown, Melanie Galvin, Nicole Simms, Francesca Trapani, Maximillian W. Schenk, Sakshi Gulati, Robert Sloane, Christopher J. Morrow, Kristopher K. Frese, Alice Lallo
Supplementary Figure 1. Combination treatment with olaparib/AZD1775 is effective in select SCLC CDX models. Mice bearing CDX3 (a), CDX4 (b), CDX8 (c), or CDX8p (d) tumors were treated with vehicles (black) AZD1775 (red), olaparib (green), or the comb
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ac53f71c3bbc840c446a75c6ba4eecb
https://doi.org/10.1158/1078-0432.22468760.v1
https://doi.org/10.1158/1078-0432.22468760.v1
Autor:
Caroline Dive, Mark J. O'Connor, Fiona Blackhall, Crispin Miller, Kathryn L. Simpson, Garima Khandelwal, Elaine Cadogan, Zhongwu Lai, Adina Hughes, Lynsey Priest, Cassandra L. Hodgkinson, Stewart Brown, Melanie Galvin, Nicole Simms, Francesca Trapani, Maximillian W. Schenk, Sakshi Gulati, Robert Sloane, Christopher J. Morrow, Kristopher K. Frese, Alice Lallo
Purpose: Introduced in 1987, platinum-based chemotherapy remains standard of care for small cell lung cancer (SCLC), a most aggressive, recalcitrant tumor. Prominent barriers to progress are paucity of tumor tissue to identify drug targets and patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7fa59bc86f133a5ab17a289354c74584
https://doi.org/10.1158/1078-0432.c.6527045
https://doi.org/10.1158/1078-0432.c.6527045
Autor:
Sandra Wimberger, Nina Akrap, Mike Firth, Johan Brengdahl, Susanna Engberg, Marie K. Schwinn, Michael R. Slater, Anders Lundin, Pei-Pei Hsieh, Songyuan Li, Silvia Cerboni, Jonathan Sumner, Burcu Bestas, Bastian Schiffthaler, Björn Magnusson, Silvio Di Castro, Preeti Iyer, Bohlooly-Y Mohammad, Thomas Machleidt, Steve Rees, Ola Engkvist, Tyrell Norris, Elaine Cadogan, Josep V. Forment, Saša Šviković, Pinar Akcakaya, Amir Taheri-Ghahfarokhi, Marcello Maresca
Genome editing tools, especially CRISPR/Cas9-based strategies, have transformed biomedical research and opened opportunities for developing curative treatments for genetic diseases. Despite rapid progress, low efficiency of targeted DNA integration a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a08601f80723c09f5557274e0ab558c2
https://doi.org/10.1101/2022.12.15.520396
https://doi.org/10.1101/2022.12.15.520396